Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Doximity's Q3 numbers beat estimates; Jefferies 'surprised at weakness' in shares

Published 09/02/2024, 09:32
Updated 09/02/2024, 09:32
© Reuters.

Doximity Inc. (NYSE:DOCS) reported better-than-anticipated earnings and revenue for the fiscal third quarter and hiked the outlook for the full year. Still, the company’s shares fell nearly 4% in after-hours trading.

The firm reported an earnings per share (EPS) of $0.29, topping the consensus estimate of $0.24. Its revenue for the quarter reached $135.3 million, surpassing the projected $127.5 million.

For the fiscal fourth quarter of 2024, Doximity anticipates revenue to be in the range of $115.9 million to $116.9 million, slightly below the expected $118.1 million. The company also projects its adjusted EBITDA to fall between $50.5 million and $51.5 million.

Looking at the full year, Doximity has revised its revenue forecast upwards to between $473.3 million and $474.3 million, from an earlier range of $460 million to $472 million. This adjustment brings the forecast above $467.2 million expected by analysts.

Furthermore, the company has adjusted its expected adjusted EBITDA to between $224.5 million and $225.5 million, up from the previously forecasted range of $207 million to $219 million, exceeding the consensus forecast of $214.3 million.

“Appreciating the Dec qtr is the strongest seasonally, DOCS reported revs and EBITDA well ahead of consensus. We are surprised by the neg reaction in after-market,” Jefferies analysts said in a note.

“We believe investors are focused on the mgt's more tepid outlook for F4Q and the prelim comments on the C24 outlook. With many recent qtrs marked by inconsistent execution and miscommunication, we like mgt taking the conservative route and expect to see a full recovery and then some in the shares,” they wrote.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.